Wolfe Research initiated coverage of Scholar Rock (SRRK) with an Outperform rating and $42 price target Scholar Rock’s manufacturing “hiccup is just a detour, not a derailment,” argues the analyst, who forecasts apitegromab to achieve blockbuster sales given its non-overlapping mechanism.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRRK:
- Scholar Rock price target raised to $45 from $44 at Barclays
- Scholar Rock’s Earnings Call: Optimism Amid Regulatory Challenges
- Buy Rating for Scholar Rock Holdings Driven by Strategic Preparations for Apitegromab’s Market Launch
- Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!
- Scholar Rock Advances SMA Treatment Amid Financial Losses